Effect of FK-506 on xenografted human Graves' thyroid tissue is severe combined immunodeficient mice.
OBJECTIVE
We studied the macrolide antibiotic FK-506, an immunosuppressive agent, in an attempt to ameliorate the lesion of autoimmune thyroid disease in human thyroid tissue xenografted into severe combined immunodeficient (SCID) mice. It was not felt appropriate to employ this agent directly in patients with autoimmune thyroid disease because adequate therapeutic modalities are available and the introduction of new, experimental agents could not be justified. Moreover, the study of the tissue before and after treatment could not have been undertaken directly in patients.


METHODS
Human thyroid xenografts from four patients with Graves' disease and two normal persons were xenografted into SCID mice. Two weeks after xenografting, human immunoglobulin G (IgG) was detectable in all SCID mice xenografted with Graves' thyroid tissue. Mice were divided into two groups with human IgG levels similar to each other. Mice in the first group were treated with FK-506 daily for 6 weeks; mice in the second (similar) group were given phosphate-buffered saline (PBS) only (control group).


METHODS
Blood samples were taken every 2 weeks from the tail veins for human IgG, thyroid stimulating antibody, thyroperoxidase antibodies, thyroglobulin antibodies, and interferon-gamma (IFN-gamma). After 8 weeks treatment, animals were sacrificed; thyroid tissue was examined histologically and for thyrocyte HLA-DR expression. FK-506 was also added to thyrocytes in in-vitro tissue culture conditions.


RESULTS
After 4-6 weeks of FK-506 therapy, human IgG, all thyroid antibodies and IFN-gamma were suppressed, while the levels remained elevated in the control group. Lymphocytic infiltration virtually disappeared in the human thyroid tissue of the FK-506-treated mice and thyrocyte HLA-DR expression markedly declined; in the control mice, lymphocytic infiltration remained heavy and HLA-DR expression remained high. On the other hand, FK-506 added directly to thyrocytes in vitro (without lymphocytes) did not reduce thyrocyte HLA-DR expression.


CONCLUSIONS
FK-506 appears to suppress the activation of intrathyroidal lymphocytes, but not thyrocytes. From these observations, it is concluded that this agent, by its action on intrathyroidal lymphocytes, is able to ameliorate the immunologically mediated histological and serological disturbance in human autoimmune thyroid disease, at least under these circumstances.
Yoshikawa
N
N
Endocrinology Research Laboratory, Wellesley Hospital, University of Toronto, ON, Canada.
Arreaza
G
G
Mukuta
T
T
Resetkova
E
E
Miller
N
N
Jamieson
C
C
Nishikawa
M
M
Inada
M
M
Volpé
R
R
D000818:Animals; D001323:Autoantibodies / Q000097:blood; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000276:immunology; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D018828:Immunoglobulins, Thyroid-Stimulating; D007371:Interferon-gamma / Q000032:analysis; D007453:Iodide Peroxidase / Q000276:immunology; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D016559:Tacrolimus / Q000627:therapeutic use*; D013954:Thyroglobulin / Q000276:immunology; D013961:Thyroid Gland / Q000276:immunology* / Q000473:pathology / Q000637:transplantation; D014183:Transplantation, Heterologous
D001323:Autoantibodies; D006684:HLA-DR Antigens; D007074:Immunoglobulin G; D018828:Immunoglobulins, Thyroid-Stimulating; D007371:Interferon-gamma; D013954:Thyroglobulin; D007453:Iodide Peroxidase; D016559:Tacrolimus